Skip to main content

news

Jones Day has advised Japan’s Astellas Pharma on its $5.9 billion acquisition of U.S. drugmaker Iveric Bio, which was represented by Skadden, Arps, Slate, Meagher & Flom and Wilmer Cutler Pickering Hale and Dorr.

This is the second-largest cross-border acquisition by a Japanese drugmaker in the past five years, following Takeda Pharmaceutical's $6 billion purchase of Nimbus Therapeutics' psoriasis drug unit that was announced last December, Reuters reported.

This acquisition, the largest for Astellas, is expected to give it access to a range of ophthalmology treatments, Reuters added.

Partner Jonn Beeson led the Jones Day team.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Trilegal, Khaitan guide RMZ-Colt $1.7 bln India data centre JV

by Nimitt Dixit |

Trilegal advised Indian alternative asset owner RMZ Group on its $1.7 billion joint venture with Colt Data Centre Services, which was advised by Khaitan & Co, to invest in the Indian data centre market, as well as the proposed acquisition of stakes in two data centre projects.

HSF, CC lead on SF Holdings’ $750 mln Hong Kong IPO

Herbert Smith Freehills, CM Law Firm, and Grandall Law Firm have advised Chinese logistics provider SF Holdings on its $750 million initial public offering in Hong Kong, with Clifford Chance and King & Wood Mallesons advising the joint sponsors.

Bakers, HSF act on PE acquisition of Japan’s jinjer

by Nimitt Dixit |

Baker & McKenzie (Gaikokuho Joint Enterprise) has advised private equity firms J-STAR Co and Potentia Capital on their joint acquisition of jinjer, one of Japan’s leading HR SaaS players. While financial terms were not recorded, news reports value the deal at $500 million.